Skip to main content
OpenTrials

Clinical trial condition

Infections, Papillomavirus

Explore clinical trials studying Infections, Papillomavirus. Study availability and eligibility vary by location and protocol.

61 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Infections, Papillomavirus trial results

Completed

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

NCT00485732

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Seoul, South Korea
  • GSK Investigational Site Seoul, South Korea
  • GSK Investigational Site Seoul, South Korea
  • GSK Investigational Site Seoul, South Korea
View Trial Details
Completed

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +24 more
Locations
  • GSK Investigational Site Mobile, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
View all 50 locations
View Trial Details
Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

NCT00426361

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Auch, France
  • GSK Investigational Site Draguignan, France
  • GSK Investigational Site Essey-lès-Nancy, France
  • GSK Investigational Site Évreux, France
View all 38 locations
View Trial Details
Completed

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

NCT01418937

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Campinas, Brazil
  • GSK Investigational Site Curitiba, Brazil
  • GSK Investigational Site Fortaleza, Brazil
View Trial Details
Completed

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

NCT00799825

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Louisville, Colorado, United States
View all 48 locations
View Trial Details
Completed

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

NCT00546078

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Augusta, Georgia, United States
  • GSK Investigational Site Bardstown, Kentucky, United States
  • GSK Investigational Site Louisville, Kentucky, United States
View all 17 locations
View Trial Details
Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

NCT00552279

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Brescia, Lombardy, Italy
  • GSK Investigational Site Lodi, Lombardy, Italy
  • GSK Investigational Site Milan, Lombardy, Italy
  • GSK Investigational Site Cagliari, Sardinia, Italy
View all 16 locations
View Trial Details

Related conditions